[go: up one dir, main page]

HRP20050070B1 - 3-2-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2-indolinon-monoetansulfonat i njegova primjena kao farmaceutskog pripravka - Google Patents

3-2-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2-indolinon-monoetansulfonat i njegova primjena kao farmaceutskog pripravka

Info

Publication number
HRP20050070B1
HRP20050070B1 HRP20050070AA HRP20050070A HRP20050070B1 HR P20050070 B1 HRP20050070 B1 HR P20050070B1 HR P20050070A A HRP20050070A A HR P20050070AA HR P20050070 A HRP20050070 A HR P20050070A HR P20050070 B1 HRP20050070 B1 HR P20050070B1
Authority
HR
Croatia
Prior art keywords
methyl
methylcarbonyl
anilino
piperazin
methylene
Prior art date
Application number
HRP20050070AA
Other languages
English (en)
Inventor
Gerald Jürgen ROTH
Günter Linz
Peter Sieger
Werner Rall
Frank Hilberg
Thomas Bock
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30469050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050070(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co.Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co.Kg
Publication of HRP20050070A2 publication Critical patent/HRP20050070A2/xx
Publication of HRP20050070B1 publication Critical patent/HRP20050070B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Prikazani izum se odnosi na spoj 3-Z-[1-(4-(N-((4-metil-piperazin-1-il)-metilkarbonil)-N-metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2-indolinon monoetansulfonat formule I i njegovu primjenu u farmaceutskom pripravku. Formula I:
HRP20050070AA 2002-07-24 2003-07-18 3-2-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2-indolinon-monoetansulfonat i njegova primjena kao farmaceutskog pripravka HRP20050070B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10233500A DE10233500A1 (de) 2002-07-24 2002-07-24 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
PCT/EP2003/007822 WO2004013099A1 (en) 2002-07-24 2003-07-18 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition

Publications (2)

Publication Number Publication Date
HRP20050070A2 HRP20050070A2 (en) 2005-12-31
HRP20050070B1 true HRP20050070B1 (hr) 2013-09-30

Family

ID=30469050

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050070AA HRP20050070B1 (hr) 2002-07-24 2003-07-18 3-2-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2-indolinon-monoetansulfonat i njegova primjena kao farmaceutskog pripravka

Country Status (35)

Country Link
US (2) US7119093B2 (hr)
EP (2) EP1527047B1 (hr)
JP (1) JP5039279B2 (hr)
KR (1) KR101145691B1 (hr)
CN (1) CN100351235C (hr)
AR (2) AR040662A1 (hr)
AT (1) ATE551322T1 (hr)
AU (1) AU2003254376B2 (hr)
BR (1) BRPI0312811B8 (hr)
CA (1) CA2493310C (hr)
CY (1) CY1112916T1 (hr)
DE (1) DE10233500A1 (hr)
DK (1) DK1527047T3 (hr)
EA (1) EA008684B1 (hr)
EC (1) ECSP055571A (hr)
EG (1) EG24562A (hr)
ES (1) ES2384968T3 (hr)
HR (1) HRP20050070B1 (hr)
IL (2) IL166405A0 (hr)
ME (1) ME00353B (hr)
MX (1) MXPA04012785A (hr)
MY (1) MY136883A (hr)
NO (1) NO330486B1 (hr)
NZ (1) NZ538367A (hr)
PE (1) PE20040704A1 (hr)
PL (1) PL223758B1 (hr)
PT (1) PT1527047E (hr)
RS (1) RS52283B (hr)
SA (1) SA03240446B1 (hr)
SI (1) SI1527047T1 (hr)
TW (1) TWI285635B (hr)
UA (1) UA78352C2 (hr)
UY (1) UY27904A1 (hr)
WO (1) WO2004013099A1 (hr)
ZA (1) ZA200409814B (hr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
EP1870400A1 (en) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
US8338422B2 (en) 2007-06-21 2012-12-25 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
PE20091445A1 (es) * 2007-12-03 2009-10-19 Boehringer Ingelheim Int Derivados de indolinona y procedimiento para su fabricacion
TR201802086T4 (tr) * 2007-12-03 2018-03-21 Boehringer Ingelheim Int Bir indolinon türevinin imalatı için proses.
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
MY158929A (en) * 2008-06-06 2016-11-30 Boehringer Ingelheim Int Pharmaceutical combination
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
DK2299987T3 (en) 2008-06-06 2018-05-22 Boehringer Ingelheim Int Pharmaceutical Capsule Dosage Form Containing A Suspension Formulation Of An Indolinone Derivative
WO2010081817A1 (en) 2009-01-14 2010-07-22 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
JP2012526766A (ja) 2009-05-14 2012-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍性及び線維性疾患の処置における新規な併用療法
US20120136004A1 (en) * 2009-05-14 2012-05-31 Boehringer Ingelheim International Gmbh New combination therapy in treatment of cancer and fibrotic diseases
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2012068441A2 (en) 2010-11-19 2012-05-24 Ratiopharm Gmbh Intedanib salts and solid state forms thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP2875020B1 (en) 2012-07-19 2017-09-06 Boehringer Ingelheim International GmbH Process for the preparation of a fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EP2945652B1 (en) 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) * 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (en) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
CA3172586A1 (en) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
US20170114323A1 (en) * 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN106008308A (zh) * 2015-03-13 2016-10-12 正大天晴药业集团股份有限公司 尼达尼布乙磺酸盐结晶
WO2016178064A1 (en) * 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CN105001143A (zh) * 2015-07-24 2015-10-28 南京正大天晴制药有限公司 一种制备高纯度乙磺酸尼达尼布的方法
CN106432042A (zh) * 2015-08-13 2017-02-22 南京华威医药科技开发有限公司 尼达尼布乙磺酸水合物的药物新晶型
WO2017077551A2 (en) * 2015-11-03 2017-05-11 Mylan Laboratories Limited An amorphous nintedanib esylate and solid dispersion thereof
CZ2016104A3 (cs) 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
EP3442534A1 (en) 2016-04-13 2019-02-20 Boehringer Ingelheim International GmbH Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer
EP3246029A1 (en) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
WO2017198202A1 (zh) * 2016-05-19 2017-11-23 上海诚妙医药科技有限公司 尼达尼布的新晶型及其制备方法及其用途
JP2019522638A (ja) 2016-05-27 2019-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ニンテダニブ及びピルフェニドンによる治療開始を判定するためのｅｃｍバイオマーカーの使用
US20190275033A1 (en) 2016-06-01 2019-09-12 Boehringer Ingelheim International Gmbh Use of ecm biomarkers for determining the treatment onset with nintedanib and pirfenidone
ITUA20164213A1 (it) 2016-06-08 2017-12-08 Olon Spa Polimorfo di nintedanib
WO2018054077A1 (en) 2016-09-26 2018-03-29 Reyoung (Suzhou) Biology Science & Technology Co., Ltd Composition for treating ocular diseases and methods of usage and making
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
WO2018160967A1 (en) * 2017-03-02 2018-09-07 Board Of Regents, The University Of Texas System Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
WO2018165865A1 (zh) * 2017-03-14 2018-09-20 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型
TWI676617B (zh) * 2017-03-15 2019-11-11 新源生物科技股份有限公司 3-z-[1-(4-(n-((4-甲基-呱嗪-1-基)-甲羰基)-n-甲基-胺基)-苯胺基)-1-苯基-亞甲基]-6-甲氧羰基-2-吲哚啉酮的晶型
TWI632133B (zh) * 2017-03-15 2018-08-11 新源生物科技股份有限公司 ３－ｚ－［１－（４－（ｎ－（（４－甲基－哌嗪－１－基）－甲羰基）－ｎ－甲基－胺基）－苯胺基）－１－苯基－亞甲基］－６－甲氧羰基－２－吲哚啉酮的晶型
CN110573161A (zh) 2017-03-28 2019-12-13 勃林格殷格翰国际有限公司 用于治疗肌营养不良的方法的尼达尼布
WO2019048974A1 (en) * 2017-09-06 2019-03-14 Glenmark Pharmaceuticals Limited PROCESS FOR PREPARING NINTEDANIB
JP7196169B2 (ja) 2017-10-23 2022-12-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 進行性線維化を伴う間質性肺疾患（ｐｆ－ｉｌｄ）の処置のための活性剤の新規組み合わせ
WO2019097112A1 (en) 2017-11-17 2019-05-23 Fermion Oy Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib
SI3761980T1 (sl) 2018-03-07 2024-06-28 Pliant Therapeutics, Inc. Aminokislinske spojine in postopki uporabe
CN113321647B (zh) 2018-06-15 2024-08-27 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN109988094B (zh) * 2019-04-29 2020-04-14 石药集团中奇制药技术（石家庄）有限公司 一种乙磺酸尼达尼布的制备方法
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
CN115361950A (zh) 2020-04-01 2022-11-18 勃林格殷格翰国际有限公司 生物标记物在治疗纤维化病症中的用途
US11304947B2 (en) 2020-05-22 2022-04-19 Qx Therapeutics Inc. Compositions and methods for treating lung injuries associated with SARS-COV-2 infections
CA3191013A1 (en) * 2020-08-07 2022-02-10 Bdr Lifesciences Private Limited An improved highly efficient process for the prepration of nintedanib and pharmaceutically acceptable salt thereof
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN113024439A (zh) * 2021-03-28 2021-06-25 郑州大学 尼达尼布乙磺酸盐新晶型ⅰ的制备
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
WO2023161668A1 (en) 2022-02-28 2023-08-31 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis
EP4572763A1 (en) 2022-08-16 2025-06-25 Boehringer Ingelheim International GmbH Pharmaceutical formulations of nintedanib for intraocular use
KR20240042322A (ko) 2022-09-23 2024-04-02 삼아제약 주식회사 티로신 키나제 저해제를 유효성분으로 하는 약제학적 조성물
EP4578443A1 (en) 2023-12-27 2025-07-02 Faran S.A. Oral suspensions comprising nintedanib esylate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027081A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma Kg In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel
WO2001027080A2 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma Kg In 5-stellung substituierte indolinone und ihre verwendung als kinase und cyclin-cdk-komplexe inhibitoren
WO2002081445A1 (de) * 2001-04-06 2002-10-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg In 6-stellung substituierte indoline und ihre verwendung als kinase-inhibitoren

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB395546A (en) 1931-10-12 1933-07-20 Robert Pauli Scherer Method of and apparatus for making capsules
US2720463A (en) 1950-11-17 1955-10-11 American Cyanamid Co Gelatin capsule casting composition preparation
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
EP0169398B1 (de) 1984-07-24 1990-08-29 R.P. Scherer GmbH Oxytetracyclin-HC1-Weichgelatinekapseln und Verfahren zu ihrer Herstellung
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
CZ298533B6 (cs) * 1999-08-23 2007-10-31 Solvay Pharmaceuticals B. V. Deriváty fenylpiperazinu, zpusob jejich prípravy a farmaceutické prostredky s jejich obsahem
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027081A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma Kg In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel
WO2001027080A2 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma Kg In 5-stellung substituierte indolinone und ihre verwendung als kinase und cyclin-cdk-komplexe inhibitoren
WO2002081445A1 (de) * 2001-04-06 2002-10-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg In 6-stellung substituierte indoline und ihre verwendung als kinase-inhibitoren

Also Published As

Publication number Publication date
EP1527047B1 (en) 2012-03-28
EA200500146A1 (ru) 2005-08-25
US7119093B2 (en) 2006-10-10
ATE551322T1 (de) 2012-04-15
MEP53708A (hr) 2011-05-10
EA008684B1 (ru) 2007-06-29
NZ538367A (en) 2008-01-31
MXPA04012785A (es) 2005-06-08
BRPI0312811B1 (pt) 2019-03-12
ZA200409814B (en) 2006-02-22
MY136883A (en) 2008-11-28
NO330486B1 (no) 2011-04-26
AR094217A2 (es) 2015-07-15
CY1112916T1 (el) 2016-04-13
KR20050042139A (ko) 2005-05-04
AU2003254376A1 (en) 2004-02-23
PE20040704A1 (es) 2004-11-29
PL372996A1 (en) 2005-08-08
EP2386543A1 (en) 2011-11-16
ME00353B (me) 2011-10-10
ES2384968T3 (es) 2012-07-16
WO2004013099A1 (en) 2004-02-12
IL166405A0 (en) 2006-01-15
AR040662A1 (es) 2005-04-13
DK1527047T3 (da) 2012-07-16
RS20050046A (en) 2007-09-21
PT1527047E (pt) 2012-06-28
EG24562A (en) 2009-10-25
HRP20050070A2 (en) 2005-12-31
US20060258681A1 (en) 2006-11-16
US20040176392A1 (en) 2004-09-09
IL166405A (en) 2009-11-18
EP1527047A1 (en) 2005-05-04
JP5039279B2 (ja) 2012-10-03
TWI285635B (en) 2007-08-21
HK1078851A1 (zh) 2006-03-24
UA78352C2 (uk) 2007-03-15
ECSP055571A (es) 2005-04-18
SA03240446B1 (ar) 2007-07-31
DE10233500A1 (de) 2004-02-19
NO20050985L (no) 2005-02-23
TW200409754A (en) 2004-06-16
RS52283B (sr) 2012-10-31
PL223758B1 (pl) 2016-10-31
CN100351235C (zh) 2007-11-28
JP2005535684A (ja) 2005-11-24
CA2493310A1 (en) 2004-02-12
SI1527047T1 (sl) 2012-07-31
BRPI0312811A8 (pt) 2019-01-02
KR101145691B1 (ko) 2012-05-25
UY27904A1 (es) 2004-02-27
CN1671660A (zh) 2005-09-21
BR0312811A (pt) 2005-04-19
BRPI0312811B8 (pt) 2021-05-25
CA2493310C (en) 2011-01-18
AU2003254376B2 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
HRP20050070B1 (hr) 3-2-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2-indolinon-monoetansulfonat i njegova primjena kao farmaceutskog pripravka
EA200700192A1 (ru) Производные фталазина в качестве ингибиторов parp
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20071074L (no) Substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
ATE449090T1 (de) Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
ATE327977T1 (de) Tetrahydrochinolin-derivate als crth2 antagonisten
PE20130239A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
IL166271A0 (en) Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
SE0202463D0 (sv) Novel compounds
TW200732324A (en) Novel compounds that are ERK inhibitors
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
ATE442846T1 (de) Piperidin- und pyrrolidin-derivate alsantagonisten des histamin-h3-rezeptors
NO20054848L (no) Substituerte p-diaminobenzenderivater
SE0403171D0 (sv) New compounds
PL376324A1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
MY139522A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
MY136859A (en) Pyrrolidine derivatives as factor xa inhibitors
MXPA05009282A (es) Derivados de anilina sustituidos.
DE60326263D1 (de) Pyrimidin-sulfonamide und ihre verwendung als endothelin-rezeptor-antagonisten
EA200600100A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4
TW200628153A (en) Novel compounds
BR0209076A (pt) Derivados de piperazino e seu uso como inibidor de pde4

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190715

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200713

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210713

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20220713

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20230718